reports
ARRAY Technologies Announces Fourth Quarter and Full Year 2025 Earning...
ARRAY Technologies Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call ALBUQUERQUE, N.M., Feb. 04, 2026 (GLOBE NEWSWIRE) -- ARRAY Technologies, Inc. (the “Company” or “ARRAY”) (NASDAQ: ARRY), a leading global provider of solar tracking technology products, software, services and foundation solutions, today announced that the Company will release its fourth quarter and full year 2025 results after the market closes on Wednesday, February 25, 2026, to be followed by a conference call at 5:00 p.m. (Eastern Time) that same day. The conference call can be acc...
- Michael Piccolo
Daily Recap: VRNS, CYBR/PANW, LYV, WBS/SAN, SLAB/TXN, SITM, RSVR, GRAB...
CyberArk Software Ltd. (CYBR - $406.67) and Palo Alto Networks, Inc. (PANW - $166.24)Target Reports Earnings; Pending Acquisition On-Track to Close Before End of April; Acquirer Stock Seems Oversold. CYBR announced record 4Q and FY'2025 financial results featuring record net new ARR of $99 million
Palomar Holdings, Inc. Announces Fourth Quarter and Full Year 2025 Fin...
Palomar Holdings, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results Release Date and Conference Call LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (the “Company”) today announced that it will release its fourth quarter and full year 2025 results after the market close on Wednesday, February 11, 2026, and will host a conference call at 12:00 p.m. (Eastern Time) the following day, Thursday, February 12, 2026. The conference call can be accessed live by dialing 1-877-423-9813 or for international callers, 1-201-689-8573, and reque...
Palomar Holdings, Inc. Completes Acquisition of The Gray Casualty & Su...
Palomar Holdings, Inc. Completes Acquisition of The Gray Casualty & Surety Company and Closes $450 Million Credit Facility LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (“Palomar”, the “Company”) today announced the completion of the previously announced acquisition of The Gray Casualty & Surety Company (“Gray Surety”), effective January 31, 2026, and the successful closing of new unsecured financing, effective January 27, 2026. The financing includes a $150 million revolving facility and a $300 million term loan. U.S. Bank National Association...
AerSale® Opens New 90,000 Sq. Ft. Aerostructures MRO Facility in Hiale...
AerSale® Opens New 90,000 Sq. Ft. Aerostructures MRO Facility in Hialeah Gardens, FL 3X facility expansion with a new 90,000 sq. ft. Aerostructures MRO operation, replacing AerSale’s former Medley, Florida locationState-of-the-art equipment added with expanded capacity for larger components to enhance reliability and turn-times now supporting widebody structures such as B777 engine nacelles and thrust reversers, including GE90 and Trent platforms MIAMI, Jan. 26, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ASLE) (the “Company”), a leading global provider of aviation aftermarket products and servic...
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter...
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones -- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product revenue of approximately $194 million, approximately 50% increase from FY2024 -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- -- On track to report topline data from 12-patient Japanese c...
ARRAY Technologies Promotes Darin Green to Global Chief Revenue Office...
ARRAY Technologies Promotes Darin Green to Global Chief Revenue Officer and Nick Strevel to Chief Product Officer ALBUQUERQUE, N.M., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology products, software, services and foundation solutions, today announced two strategic leadership promotions that reinforce the company’s commitment to accelerating growth and advancing product development across global markets. “Darin Green and Nick Strevel have demonstrated exceptional leadership and vision, ...
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Pha...
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome -- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS -- -- Company initiated Phase 1, Part D study to evaluate weekly MC4R agonist RM-718 in patients with PWS -- -- Company to hold conference call on ...
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory P...
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Thursday, December 11 at 8:00 a.m. ET to disclose preliminary data from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS)...
ARRAY Technologies, Inc. to Participate in Upcoming Events for the Inv...
ARRAY Technologies, Inc. to Participate in Upcoming Events for the Investor Community ALBUQUERQUE, N.M., Nov. 14, 2025 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology and fixed-tilt products, foundation solutions, software systems and services, today announced that members of its senior management team are scheduled to participate in the following events for the investor community in November and December. Jefferies Fireside ChatAttendees: Kevin Hostetler, CEO November 19, 2025Virtual UBS Global Tec...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
35G GENPACT LIMITED
EXPE EXPEDIA GROUP INC.
CRK COMSTOCK RESOURCES INC.
AXTI AXT INC.
ALB ALBEMARLE CORPORATION
ACRE ARES COMMERCIAL REAL ESTATE
AGO ASSURED GUARANTY LTD.
HRTG HERITAGE INSURANCE HOLDINGS INC.
DRH DIAMONDROCK HOSPITALITY COMPANY
ELY CALLAWAY GOLF COMPANY
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
TALO TALOS ENERGY INC.
LASR NLIGHT
GLOB GAZIT-GLOBE LTD.
ARVN ARVINAS HOLDING
PLMR PALOMAR HOLDINGS
BW BABCOCK & WILCOX ENTERPRISES
TXG 10X GENOMICS INC CLASS A
PGNY PROGYNY
AMPY AMPLIFY ENERGY
EOSE EOS ENERGY ENTERPRISES INC (A)
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
DOCN DIGITALOCEAN HLDGS INC
DSGN DESIGN THERAPEUTICS INC
FIGS FIGS INC
YOU ONTO INNOVATION INC.
PPTA CLEAR SECURE INC
AMPX PERPETUA RESOURCES CORP
OS AMPRIUS TECHNOLOGIES INC
SNDK ONESTREAM INC
CSIOX SANDISK CORP
BALY CATALYST PERINI STRATEGIC INCOM ORD
HOII BALLY'S CORPORATION
REX HOOD GROWTH & INCOME ETF
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at Obes...
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 – Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data from Phase 3 TRANSCEND trial show clinically meaningful changes in cardiometabolic parameters in patients with acquired hypothalamic obesity treated with setmelanotide for 52 weeks – BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceu...
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IM...
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity -- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review period for...
Palomar Holdings, Inc. Reports Third Quarter 2025 Results
Palomar Holdings, Inc. Reports Third Quarter 2025 Results LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or “Company”) reported net income of $51.5 million, or $1.87 per diluted share, for the third quarter of 2025 compared to net income of $30.5 million, or $1.15 per diluted share, for the third quarter of 2024. Adjusted net income(1) was $55.2 million, or $2.01 per diluted share, for the third quarter of 2025 as compared to $32.4 million, or $1.23 per diluted share, for the third quarter of 2024. Third Quarter 2025 Highlights Gross...
ARRAY Technologies, Inc. Reports Financial Results for the Third Quart...
ARRAY Technologies, Inc. Reports Financial Results for the Third Quarter 2025 Exceptional momentum continues with year-to-date revenue up 65% and volume up 74% 2025 Third Quarter Highlights Successfully completed acquisition of APA Solar (APA), a leading provider of foundations, fixed-tilt and solar racking solutionsTotal executed contracts and awarded orders at September 30, 2025 were $1.9 billion, excluding APA(2)Revenue of $393.5 million APA contributed revenue of $16.9 million Gross Margin of 26.9%Adjusted gross margin(1) of 28.1%Net income to common shareholders of $18....
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (s...
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHB BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it has e...
Rhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® ...
Rhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés IMCIVREE est désormais remboursé pour le cadre de la gestion du poids chez les patients atteints du syndrome de Bardet-Biedl (BBS) en Ontario, en Alberta, en Colombie-Britannique, en Saskatchewan, en Nouvelle-Écosse et dans le cadre du programme SSNA BOSTON, 05 nov. 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq : RYTM), une société biopharmaceutique internationale axée sur la transforma...
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results an...
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update -- Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million -- -- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity -- -- Company is on track to report preliminary results from setmelanotide Phase 2 trial in Prader-Willi syndrome in fourth quarter of 2025 -- -- German observational study showed setmelanotide therapy was associated with improvement in measures of MASLD and kidney function in BBS patients -- ...
Palomar Holdings, Inc. Announces Agreement to Acquire The Gray Casualt...
Palomar Holdings, Inc. Announces Agreement to Acquire The Gray Casualty & Surety Company Builds Scale in the Attractive Surety Market LA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (“Palomar”, the “Company”) today announced that it has entered into a definitive agreement to acquire The Gray Casualty & Surety Company (“Gray Surety”) from Bernhard Capital Partners (“BCP”) and The Gray Insurance Company for total consideration of $300 million in cash subject to customary closing adjustments. The transaction has been approved by both Gray Surety an...
Palomar Holdings, Inc. Announces Third Quarter 2025 Financial Results ...
Palomar Holdings, Inc. Announces Third Quarter 2025 Financial Results Release Date and Conference Call LA JOLLA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (the “Company”) today announced that it will release its third quarter 2025 results after market close on Thursday, November 6, 2025, and will host a conference call at 12:00 p.m. (Eastern Time) the following day, Friday, November 7, 2025. The conference call can be accessed live by dialing 1-877-423-9813 or for international callers, 1-201-689-8573, and requesting to be joined to the Palomar Third...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.